Cyclopharm H1 2026 Sees US Revenue Surge by 74%
UKPulse Money Desk
Cyclopharm's H1 2026 results show a significant 74% increase in US revenue, despite overall slides. New guidelines are also reported to improve the company's outlook.
- Cyclopharm's US revenue surged by 74% in H1 2026.
- New guidelines are boosting Cyclopharm's outlook.
- Cyclopharm's H1 2026 results show overall slides.
Cyclopharm has reported a substantial 74% increase in its US revenue for the first half of 2026. This surge comes despite overall slides in the company's H1 2026 performance.
The company's outlook is reportedly receiving a boost from new guidelines, suggesting potential positive developments for Cyclopharm moving forward.